Treatment of Inoperable Non-small Cell Lung Carcinoma Stage IIIB and IV with Cisplatin, Epidoxorubicin, Vindesine and Lonidamine: A Phase II Study
| Autor: | L. Portalone, Anna Rita Cruciani, Franco Salvati, N Perrone, Francesco Nunziati, A. Lombardi, Antonio Antilli, V Magliacani, L Mugnaini, Mauro Signora |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Indazoles Lung Neoplasms Vindesine Phases of clinical research Gastroenterology 030218 nuclear medicine & medical imaging 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Aged Epirubicin Neoplasm Staging Cisplatin Antibiotics Antineoplastic business.industry Lonidamine General Medicine Middle Aged medicine.disease Antineoplastic Agents Phytogenic Acute toxicity Regimen Treatment Outcome Oncology chemistry Doxorubicin 030220 oncology & carcinogenesis Toxicity Female business medicine.drug |
| Zdroj: | Tumori Journal. 85:239-242 |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.1177/030089169908500405 |
| Popis: | Aims and Background The polychemotherapeutic regimen PEV (cisplatin, epidoxorubicin and vindesine) + lonidamine proved to be valid in terms of activity and efficacy in the treatment of patients with advanced, previously untreated non-small cell lung carcinoma. The goal of the study was to verify whether a different dose of lonidamine, together with an increase in cisplatin and epidoxorubicin compared to the standard regimen, is able to improve the activity and efficacy of PEV without increasing toxicity. Patients and Methods Thirty-one patients were treated with cisplatin (80 mg/m2/iv), epidoxorubicin (70 mg/m2/iv) and vindesine (3 mg/m2/iv) every 28 days for 6 courses in combination with lonidamine (600 mg/day on days 1 and 2 of each course followed by 450 mg/day until progression of disease or intolerance). All the patients were monitored for clinical response, median duration of response and survival and for toxicity. Results The clinical response in the 29 assessable patients was: 41.4% partial remission, 48.3% stable disease, and 10.3% progression of disease. The median duration of response was 8.5 months (range, 4-26+) and median survival was 12 months (range, 4-26+). Survival was above the median in 15 stage lIIb patients, and 2 patients were long survivors at 26+ months. The toxicity of PEV + lonidamine was mild; there were no toxic deaths nor acute toxicity of grade 4 according to the WHO scoring system. Conclusions Our polychemotherapeutic regimen proved to be valid in terms of activity and efficacy, and a further dose increase in single chemotherapeutic agents as well as lonidamine could therefore be justified. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|